{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:07:14Z","timestamp":1791864434297,"version":"4.3.4"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejps.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T18:05:20Z","timestamp":1528221920000},"page":"356-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"special_numbering":"C","title":["Safer anti-inflammatory therapy through dual COX-2\/5-LOX inhibitors: A structure-based approach"],"prefix":"10.1016","volume":"121","author":[{"given":"Jaismy Jacob","family":"P","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Manju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Ethiraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.06.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700026","article-title":"Benzodioxole\u2013pyrazole hybrids as anti-inflammatory and analgesic agents with COX-1, 2\/5-LOX inhibition and antioxidant potential","volume":"350","author":"Abd El Razik","year":"2017","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejps.2018.06.003_bb0010","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ejmech.2016.11.006","article-title":"Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs\/LOX inhibitors endowed with anti-inflammatory activity","volume":"127","author":"Abdelrahman","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2005.12.006","article-title":"Inflammation: a pivotal link between autoimmune diseases and atherosclerosis","volume":"5","author":"Abou-Raya","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/14756366.2010.550890","article-title":"Synthesis and biological evaluation of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives with both COX and LOX inhibitory activity","volume":"26","author":"Akhter","year":"2011","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jmgm.2015.06.006","article-title":"The study of dual COX-2\/5-LOX inhibitors by using electronic-topological approach based on data on the ligand\u2013receptor interactions","volume":"60","author":"Aksakal","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejps.2018.06.003_bb0030","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1476-5381.2009.00322.x","article-title":"Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages","volume":"157","author":"Altavilla","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1476-5381.2012.01969.x","article-title":"Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia","volume":"167","author":"Altavilla","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0040","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1093\/rheumatology\/keh105","article-title":"Licofelone\u2014clinical update on a novel LOX\/COX inhibitor for the treatment of osteoarthritis","volume":"43","author":"Alvaro-Gracia","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejps.2018.06.003_bb0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/pr.108.00001","article-title":"Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis","volume":"60","author":"Anderson","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0050","first-page":"A1122","article-title":"Gastrointestinal (GI) profile of tepoxalin (TX), an orally active dual cyclooxygenase (CO)\/lipoxygenase (LO) inhibitor with potent antiinflammatory activity","volume":"4","author":"Anderson","year":"1990","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2018.06.003_bb0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bmc.2012.10.046","article-title":"Synthesis and biological evaluation of some 5-arylidene-2-(1, 3-thiazol-2-ylimino)-1, 3-thiazolidin-4-ones as dual anti-inflammatory\/antimicrobial agents","volume":"21","author":"Apostolidis","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0060","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.lfs.2005.11.017","article-title":"Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase","volume":"78","author":"Araico","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0065","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.lfs.2007.03.017","article-title":"Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2\/5-lipoxygenase inhibitor","volume":"80","author":"Araico","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-3565(25)24025-3","article-title":"Tepoxalin: a dual cyclooxygenase\/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile","volume":"271","author":"Argentieri","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.06.003_bb0075","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0960-894X(02)00013-6","article-title":"Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2\/5-lipoxygenase inhibitor","volume":"12","author":"Barbey","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1988.tb03277.x","article-title":"The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin","volume":"25","author":"Barr","year":"1988","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0085","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/0006-2952(84)90346-0","article-title":"Dual inhibition of cyclooxygenase and lipoxygenase by 2-acetylthiophene 2-thiazolylhydrazone (CBS-1108) and effect on leukocyte migration in vivo","volume":"33","author":"Bertez","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0090","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/art.1780340212","article-title":"Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis","volume":"34","author":"Blackburn","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejps.2018.06.003_bb0095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF01966309","article-title":"FPL 62064, a topically active 5-lipoxygenase\/cyclooxygenase inhibitor","volume":"30","author":"Blackham","year":"1990","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejps.2018.06.003_bb0100","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/jm0613166","article-title":"Structural and functional basis of cyclooxygenase inhibition","volume":"50","author":"Blobaum","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0960-894X(00)80657-5","article-title":"Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase","volume":"2","author":"Boschelli","year":"1992","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0110","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1073\/pnas.94.12.6148","article-title":"Discovery of a second 15S-lipoxygenase in humans","volume":"94","author":"Brash","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.06.003_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.11.013","article-title":"Discovery of novel hybrids of diaryl-1, 2, 4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy","volume":"108","author":"Cai","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0125","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.intimp.2009.06.001","article-title":"The anti-inflammatory pharmacology of Pycnogenol\u00ae in humans involves COX-2 and 5-LOX mRNA expression in leukocytes","volume":"9","author":"Canali","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0130","series-title":"The Leukotrienes: Chemistry and Biology","author":"Chakrin","year":"2012"},{"key":"10.1016\/j.ejps.2018.06.003_bb0135","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1016\/j.bmc.2006.07.047","article-title":"Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs)","volume":"14","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bmc.2009.12.008","article-title":"Discovery of 3-(4-bromophenyl)-6-nitrobenzo [1.3. 2] dithiazolium ylide 1, 1-dioxide as a novel dual cyclooxygenase\/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-\u03b1 production","volume":"18","author":"Chen","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0145","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1016\/j.bmcl.2008.10.009","article-title":"Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2 (1H) one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity","volume":"18","author":"Chowdhury","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0150","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bmcl.2008.12.066","article-title":"Synthesis of 1-(methanesulfonyl-and aminosulfonylphenyl) acetylenes that possess a 2-(N-difluoromethyl-1, 2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity","volume":"19","author":"Chowdhury","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0155","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.bmcl.2009.10.083","volume":"19","author":"Chowdhury","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0160","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/jm8015188","article-title":"Synthesis of celecoxib analogues possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity","volume":"52","author":"Chowdhury","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0165","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/j.bmcl.2010.07.132","article-title":"Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors","volume":"20","author":"Chowdhury","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0170","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2174\/1381612033454054","article-title":"Cyclooxygenase-2 biology","volume":"9","author":"Cl\u00e0ria","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2018.06.003_bb0175","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2018.06.003_bb0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.farmac.2004.09.002","article-title":"Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors","volume":"60","author":"Cusan","year":"2005","journal-title":"Il Farmaco"},{"key":"10.1016\/j.ejps.2018.06.003_bb0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0165-6147(03)00077-4","article-title":"Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors","volume":"24","author":"de Gaetano","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0190","doi-asserted-by":"crossref","first-page":"P302","DOI":"10.1016\/j.jalz.2013.05.619","article-title":"Licofelone: a dual COX\/5-LOX inhibitor attenuates intracerebroventricular streptozotocin-induced cognitive deficit, oxidative stress and neuro-inflammatory cytokines in rats","volume":"9","author":"Deshmukh","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejps.2018.06.003_bb0195","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2018.06.003_bb0200","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.biopha.2011.06.009","article-title":"Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors","volume":"65","author":"Ding","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejps.2018.06.003_bb0205","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1021\/jm0402059","article-title":"Adverse cardiovascular effects of the coxibs","volume":"48","author":"Dogn\u00e9","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejmech.2011.10.029","article-title":"Fragment-based design, docking, synthesis, biological evaluation and structure\u2013activity relationships of 2-benzo\/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase\/lipoxygenase inhibitors","volume":"47","author":"Eleftheriou","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bioorg.2017.03.012","article-title":"New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1\/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study","volume":"72","author":"El-Miligy","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4155\/fmc-2016-0230","article-title":"New benzothiophene derivatives as dual COX-1\/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study","volume":"9","author":"El-Miligy","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0225","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejps.2018.06.003_bb0230","first-page":"1","article-title":"DuCLOX-2\/5 inhibition: a promising target for cancer chemoprevention","author":"Gautam","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejps.2018.06.003_bb0235","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bmcl.2013.11.015","article-title":"Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2\/5-lipoxygenase inhibitors: synthesis, COX\/LOX inhibition, molecular modeling, and insights into their cytotoxicities","volume":"24","author":"Ghatak","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.fct.2015.05.022","article-title":"The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update","volume":"83","author":"Ghosh","year":"2015","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1197203","article-title":"The structure of human 5-lipoxygenase","volume":"331","author":"Gilbert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejps.2018.06.003_bb0250","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1096\/fj.12-205286","article-title":"Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663","volume":"26","author":"Gilbert","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2018.06.003_bb0255","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/biof.1033","article-title":"Trihydroxyflavones with antioxidant and anti-inflammatory efficacy","volume":"38","author":"Gomes","year":"2012","journal-title":"Biofactors"},{"key":"10.1016\/j.ejps.2018.06.003_bb0260","first-page":"113","article-title":"Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism","volume":"32","author":"Griswold","year":"1990","journal-title":"Agents Actions Suppl."},{"key":"10.1016\/j.ejps.2018.06.003_bb0265","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0006-2952(91)90042-4","article-title":"Pharmacology of the pyrroloimidazole, SK&F 105809\u2014II: antiinflammatory activity and inhibition of mediator production in vivo","volume":"42","author":"Griswold","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-011209-153129","article-title":"Emotion recollected in tranquility: lessons learned from the COX-2 saga","volume":"61","author":"Grosser","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejps.2018.06.003_bb0275","first-page":"A818","article-title":"Multiple-dose pharmacokinetics of the antiinflammatory drug, CI-1004, in healthy subjects after 3-weeks of once-daily dosing","volume":"14","author":"Guttendorf","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0280","first-page":"A818","article-title":"Single-dose pharmacokinetics and dose proportionality of the antiinflammatory drug, CI-1004, in healthy subjects","volume":"14","author":"Guttendorf","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0285","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/bmj.284.6326.1365","article-title":"Benoxaprofen: side-effect profile in 300 patients","volume":"284","author":"Halsey","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejps.2018.06.003_bb0290","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1021\/jm950563z","article-title":"Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity","volume":"39","author":"Hamer","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.18433\/J3VW2F","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh","year":"2014","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0300","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bmj.284.6326.1368","article-title":"Side effects of benoxaprofen","volume":"284","author":"Hindson","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejps.2018.06.003_bb0305","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s000110050347","article-title":"ER-34122, a novel dual 5-lipoxygenase\/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model","volume":"47","author":"Horizoe","year":"1998","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0310","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.intimp.2009.02.003","article-title":"Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis","volume":"9","author":"Hyde","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0315","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/jm9906015","article-title":"Novel antiarthritic agents with 1, 2-isothiazolidine-1, 1-dioxide (\u03b3-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase","volume":"43","author":"Inagaki","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0320","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.bmcl.2004.02.099","article-title":"Simple aromatic compounds containing propenone moiety show considerable dual COX\/5-LOX inhibitory activities","volume":"14","author":"Jahng","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0325","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/jm970679q","article-title":"New cyclooxygenase-2\/5-lipoxygenase inhibitors. 1. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent","volume":"41","author":"Janusz","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0330","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/jm970680p","article-title":"New cyclooxygenase-2\/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring","volume":"41","author":"Janusz","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0335","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1021\/jm9802416","article-title":"New cyclooxygenase-2\/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position","volume":"41","author":"Janusz","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0340","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1039\/c3ob41936c","article-title":"Discovery of potential anti-inflammatory drugs: diaryl-1, 2, 4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase","volume":"12","author":"Jiang","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0345","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cmdc.201100460","article-title":"Aspirin analogues as dual cyclooxygenase-2\/5-lipoxygenase inhibitors: synthesis, nitric oxide release, molecular modeling, and biological evaluation as anti-inflammatory agents","volume":"7","author":"Kaur","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejps.2018.06.003_bb0350","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1432-1327.1999.00818.x","article-title":"Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase","volume":"266","author":"Kilty","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0355","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0022-3565(24)36889-2","article-title":"Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective\/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation","volume":"282","author":"Kirchner","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2018.06.003_bb0360","series-title":"Lipoxygenase Pathway of the Arachidonate Cascade, eLS","author":"Kobe","year":"2013"},{"key":"10.1016\/j.ejps.2018.06.003_bb0365","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrrheum.2014.1","article-title":"Persisting eicosanoid pathways in rheumatic diseases","volume":"10","author":"Korotkova","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0370","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/384644a0","article-title":"Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents","volume":"384","author":"Kurumbail","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2018.06.003_bb0375","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1016\/j.bmcl.2010.10.056","article-title":"Synthesis and biological evaluation of 3-[4-(amino\/methylsulfonyl) phenyl] methylene-indolin-2-one derivatives as novel COX-1\/2 and 5-LOX inhibitors","volume":"20","author":"Lai","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0380","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ejmech.2016.08.013","article-title":"Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: synthesis, biological activities in vitro and docking study","volume":"123","author":"Lamie","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0385","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/09540105.2016.1272554","article-title":"Myrica rubra leaves as a potential source of a dual 5-LOX\/COX inhibitor","volume":"28","author":"Langhansova","year":"2017","journal-title":"Food Agric. Immunol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0390","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ardp.19973300908","article-title":"Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors","volume":"330","author":"Laufer","year":"1997","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejps.2018.06.003_bb0395","series-title":"Inflammation and Rheumatic Diseases: The Molecular Basis of Novel Therapies","author":"Laufer","year":"2003"},{"key":"10.1016\/j.ejps.2018.06.003_bb0400","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1248\/bpb.29.361","article-title":"Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect","volume":"29","author":"Lee","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2018.06.003_bb0405","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2174\/0929867024606713","article-title":"New trends in dual 5-LOX\/COX inhibition","volume":"9","author":"Leval","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0410","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199009063231006","article-title":"Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases","volume":"323","author":"Lewis","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.06.003_bb0415","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejphar.2009.02.032","article-title":"The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase\/5-lipoxygenase inhibitor","volume":"607","author":"Li","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0420","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.bmc.2011.01.043","article-title":"Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1\/2 and 5-lipoxygenase","volume":"19","author":"Li","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejps.2017.06.006","article-title":"Pharmacological evaluation and molecular docking of new di-tert-butylphenol compound, LQFM-091, a new dual 5-LOX\/COX inhibitor","volume":"106","author":"Lino","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.06.003_bb0430","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1016\/j.bmc.2015.06.008","article-title":"Structure based library design (SBLD) for new 1, 4-dihydropyrimidine scaffold as simultaneous COX-1\/COX-2 and 5-LOX inhibitors","volume":"23","author":"Lokwani","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0435","series-title":"Google Patents","article-title":"Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation","author":"Loomans","year":"1987"},{"key":"10.1016\/j.ejps.2018.06.003_bb0440","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1038\/sj.bjp.0706400","article-title":"The role of inflammation in CNS injury and disease","volume":"147","author":"Lucas","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0445","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1021\/acs.biochem.5b01378","article-title":"Crystal structure of aspirin-acetylated human cyclooxygenase-2: insight into the formation of products with reversed stereochemistry","volume":"55","author":"Lucido","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2018.06.003_bb0450","series-title":"Biosynthesis and Biological Role of Leukotrienes in B Lymphocytes","author":"Mahshid","year":"2006"},{"key":"10.1016\/j.ejps.2018.06.003_bb0455","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1126\/science.289.5486.1933","article-title":"The productive conformation of arachidonic acid bound to prostaglandin synthase","volume":"289","author":"Malkowski","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejps.2018.06.003_bb0460","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/ard.62.6.501","article-title":"Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs","volume":"62","author":"Martel-Pelletier","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2018.06.003_bb0465","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12017-015-8351-0","article-title":"A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury","volume":"17","author":"Minutoli","year":"2015","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.ejps.2018.06.003_bb0470","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.bmc.2013.02.033","article-title":"Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan\u2013CD44v6 pathway and inducing cytotoxicity in colon cancer cells","volume":"21","author":"Misra","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0475","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1016\/j.bmc.2006.03.054","article-title":"Synthesis and biological evaluation of acyclic triaryl (Z)-olefins possessing a 3, 5-di-tert-butyl-4-hydroxyphenyl pharmacophore: dual inhibitors of cyclooxygenases and lipoxygenases","volume":"14","author":"Moreau","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0480","doi-asserted-by":"crossref","first-page":"7716","DOI":"10.1016\/j.bmc.2006.08.008","article-title":"Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl) acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases","volume":"14","author":"Moreau","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0485","first-page":"1808","article-title":"Docking and QSAR studies of novel (E)-3-(4-methanesulfonylphenyl)-2-(aryl) acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases","volume":"2","author":"Nematollahi","year":"2010","journal-title":"Int. J. ChemTech Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0490","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1074\/jbc.M116.725713","article-title":"Substrate-selective inhibition of cyclooxygeanse-2 by fenamic acid derivatives is dependent on peroxide tone","volume":"291","author":"Orlando","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0495","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsb.2014.11.005","article-title":"The structure of ibuprofen bound to cyclooxygenase-2","volume":"189","author":"Orlando","year":"2015","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0500","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.mce.2006.03.038","article-title":"The 5 lipoxygenase system in the vasculature: emerging role in health and disease","volume":"252","author":"Osher","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0505","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bmc.2012.03.021","article-title":"Synthesis and biological evaluation of isoxazolo [4, 5-d] pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents","volume":"20","author":"\u00d6zadal\u0131","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0510","article-title":"Nonsteroidal anti-inflammatory therapy: a journey toward safety","author":"Pereira-Leite","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0515","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1021\/jm0407761","article-title":"New COX-2\/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy","volume":"47","author":"Pommery","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0520","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejmech.2010.10.035","article-title":"Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities","volume":"46","author":"Pontiki","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejps.2018.06.003_bb0525","first-page":"453","article-title":"Identification of triazole bridged amino acids appended indoles as dual inhibitors of 5-LOX and COX-2 enzymes","volume":"9","author":"Prasher","year":"2016","journal-title":"Int. J. ChemTech Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0530","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/jm0510474","article-title":"Synthesis and structure-activity relationship studies of 1, 3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases","volume":"49","author":"Praveen Rao","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0535","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1016\/j.bmcl.2005.07.036","article-title":"Synthesis and biological evaluation of 1, 3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases","volume":"15","author":"Rao","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0540","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jpba.2006.04.020","article-title":"Rationalization of physicochemical characters of 1, 5-diarylpyrazole analogs as dual (COX-2\/LOX-5) inhibitors: a QSAR approach","volume":"42","author":"Revathi","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2018.06.003_bb0545","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0550","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1021\/cr2002799","article-title":"Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways","volume":"111","author":"Rouzer","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0555","series-title":"Leukotrienes and Prostacyclin","first-page":"15","article-title":"The leukotrienes: mediators of immediate hypersensitivity reactions and inflammation","author":"Samuelsson","year":"1983"},{"key":"10.1016\/j.ejps.2018.06.003_bb0560","first-page":"1","article-title":"2, 3-Diarylxanthones as potential inhibitors of arachidonic acid metabolic pathways","author":"Santos","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.ejps.2018.06.003_bb0565","first-page":"316","article-title":"Anti-oxidant and anti-inflammatory activities of synthetic 2, 4-bis (aryl\/heteroaryl)-5-acylthiazole derivatives","volume":"4","author":"Sathya","year":"2014","journal-title":"Asian J. Biochem. Pharm. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0570","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ejmech.2007.09.007","article-title":"Investigations concerning the COX\/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4, 5-diaryl isoselenazoles","volume":"43","author":"Scholz","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0575","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bmc.2008.11.074","article-title":"Diaryl-dithiolanes and-isothiazoles: COX-1\/COX-2 and 5-LOX-inhibitory, OH scavenging and anti-adhesive activities","volume":"17","author":"Scholz","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0580","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/BF02978843","article-title":"The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin","volume":"30","author":"Shanmugam","year":"2007","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0585","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1124\/mol.109.063115","article-title":"Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids","volume":"77","author":"Sharma","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0590","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1016\/j.bmcl.2017.07.020","article-title":"Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX","volume":"27","author":"Shen","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0595","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2011.05.010","article-title":"Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma","volume":"309","author":"Shi","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2017.06.027","article-title":"Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity","author":"Shrivastava","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0605","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0610","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejmech.2015.04.044","article-title":"Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: dual inhibition of 5-LOX and COX-2 enzymes","volume":"97","author":"Singh","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0615","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1021\/acs.jmedchem.5b00952","article-title":"Triblock conjugates: identification of a highly potent antiinflammatory agent","volume":"58","author":"Singh","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0620","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-7306(02)36015-0","article-title":"The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways","volume":"36","author":"Smith","year":"2002","journal-title":"New Compr. Biochem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0625","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0630","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1021\/cr2002992","article-title":"Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis","volume":"111","author":"Smith","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2018.06.003_bb0635","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bmj.284.6326.1372","article-title":"Fatal cholestatic jaundice in elderly patients taking benoxaprofen","volume":"284","author":"Taggart","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.ejps.2018.06.003_bb0640","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1016\/j.bmc.2011.09.003","article-title":"Design, synthesis and biological evaluation of benzo [1.3. 2] dithiazolium ylide 1, 1-dioxide derivatives as potential dual cyclooxygenase-2\/5-lipoxygenase inhibitors","volume":"19","author":"Tan","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0645","first-page":"63","article-title":"L-652,343: a novel dual 5-lipoxygenase\/cyclooxygenase inhibitor","volume":"16","author":"Tischler","year":"1985","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"10.1016\/j.ejps.2018.06.003_bb0650","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0223-5234(02)01418-6","article-title":"Cyclooxygenase-1\/2 (COX-1\/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6, 7-diaryl-2, 3-1H-dihydropyrrolizine type","volume":"37","author":"Ulbrich","year":"2002","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0655","series-title":"Advances in Eicosanoid Research","first-page":"1","article-title":"The mechanism of action of anti-inflammatory drugs","author":"Vane","year":"2000"},{"key":"10.1016\/j.ejps.2018.06.003_bb0660","doi-asserted-by":"crossref","first-page":"22152","DOI":"10.1074\/jbc.M110.119867","article-title":"Structural basis of fatty acid substrate binding to cyclooxygenase-2","volume":"285","author":"Vecchio","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0665","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(93)91057-O","article-title":"Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy","volume":"105","author":"Wallace","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejps.2018.06.003_bb0670","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/BF02001910","article-title":"Effects of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism","volume":"41","author":"Weisman","year":"1994","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejps.2018.06.003_bb0675","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1552-4604.1991.tb03743.x","article-title":"Nonsteroidal anti-inflammatory drugs: effects on kidney function","volume":"31","author":"Whelton","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0680","first-page":"II-2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2018.06.003_bb0685","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.06.003_bb0690","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF01987895","article-title":"Antiarthritic profile of BF-389\u2014a novel anti-inflammatory agent with low ulcerogenic liability","volume":"37","author":"Wong","year":"1992","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejps.2018.06.003_bb0695","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2009.03.062","article-title":"Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX\/5-LOX inhibitor","volume":"611","author":"Xu","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0700","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1742-7843.2009.00463.x","article-title":"Biological evaluation of 2-(4-amino-phenyl)-3-(3, 5-dihydroxylphenyl) propenoic acid","volume":"105","author":"Xu","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0705","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.taap.2013.05.025","article-title":"Inhibition of inflammatory mediators contributes to the anti-inflammatory activity of KYKZL-1 via MAPK and NF-\u03baB pathway","volume":"272","author":"Xu","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0710","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1074\/jbc.M113.517987","article-title":"Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding network","volume":"289","author":"Xu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0030055","article-title":"Dynamic simulations on the arachidonic acid metabolic network","volume":"3","author":"Yang","year":"2007","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejps.2018.06.003_bb0720","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.bmcl.2010.02.040","article-title":"Synthesis and biological evaluation of N-difluoromethyl-1, 2-dihydropyrid-2-one acetic acid regioisomers: dual inhibitors of cyclooxygenases and 5-lipoxygenase","volume":"20","author":"Yu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2018.06.003_bb0725","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1016\/j.bmc.2005.12.062","article-title":"Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues","volume":"14","author":"Zheng","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2018.06.003_bb0730","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718302598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:51:05Z","timestamp":1760529065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718302598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":146,"alternative-id":["S0928098718302598"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.06.003","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safer anti-inflammatory therapy through dual COX-2\/5-LOX inhibitors: A structure-based approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}